Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Ionis and Roche agree on dry AMD treatment deal

Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.

Read More »

HIV Treatments That Could Make Redfield’s Prediction a Reality to Defeat AIDS Epidemic

Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.

Read More »

J&J, Arrowhead reach gene-silencing drug deal

J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.

Read More »

One Drop’s Apple Watch App Points to Trend in Wearable Health Devices

Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.

Read More »

Supernus Pharma to Buy Biscayne Neurotherapeutics in Potential $183 Million Deal

Rockville, Maryland-based Supernus Pharmaceuticals is acquiring Biscayne Neurotherapeutics, which is located in Miami.

Read More »

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Pfizer

Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.

Read More »

FDA Clears SPR Therapeutics’ Non-Opioid Neurostimulation Pain Therapies

The U.S. Food and Drug Administration cleared Cleveland-based SPR Therapeutics’ SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems for controlling pain.

Read More »

Novo Nordisk’s Semaglutide Hits Mark in T2D Trial

Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.

Read More »

Japan’s Eisai sets price tag of about $16,000 on liver cancer drug

Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.

Read More »

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom